Announced Date: 2025-09-03 (September 3, 2024)
Asset Name: Four siRNA programs
Licensor: Shanghai Argo Biopharmaceutical (China)
Licensee (Buyer): Novartis Pharma
.
Scope of Authority:
An option granted to Novartis to license ex-China rights to
two discovery-stage next generation molecules for the treatment of severe hypertriglyceridemia (sHTG) and mixed dyslipidemia；(target may APOC3)
.
and a right of first negotiation to BW-00112 (ANGPTL3), which is currently in Phase II in the U.S. and China, following a combination trial conducted by Argo.
.
License with reciprocal options to share in Profit & Loss (P&L) in the U.S. and China for an additional hepatic-delivered siRNA candidate currently in IND-enabling studies and expected to commence a multi-territorial Phase I in 2026. Novartis to receive an ex-China license to the molecule along with a P&L option in China while Argo to receive a P&L option in the U.S.
.
.
Payment Detail:
Argo will receive an upfront payment of $160 million，
Eligible to receive potential milestone and option payments of a combined potential value of up to $5.2 billion,
As well as tiered royalties on commercial sales.
In addition, Novartis has expressed its non-binding intention to participate in Argo’s next round of equity financing.
.
Link:
